Susan A Slaugenhaupt

USPTO Granted Patents = 10 (Patent Applications = 7)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 2.7

ph-index = 2

Forward Citations = 14(Granted Patents)

Location History:

Quincy, MA (US) (1999 - 2008)
Hignham, MA (US) (2020)
Hingham, MA (US) (2010 - 2023)

Company Filing History:

10 out of 2,893

The General Hospital Corporation

patents

2 out of 3,539

The United States of America, As Represented by the Secretary, Department of Health and Human Services

where one patent can have more than one assignee

Years Active: 1999-2023

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11702417 - Compounds for improving mRNA splicing (2023-07-18),

2. 10676475 - Compounds for improving mRNA splicing (2020-06-09),

3. 9265766 - Methods for altering mRNA splicing and treating familial dysautonomia by administering benzyladenine (2016-02-23),

4. 8729025 - Methods for altering MRNA splicing and treating familial dysautonomia by administering kinetin, benzyladenine, and tocotrienols (2014-05-20),

5. 7737110 - Methods for altering mRNA splicing and treating familial dysautonomia and other mechanistically related disorders (2010-06-15),

6. 7407756 - Methods for detecting mutations associated with familial dysautonomia (2008-08-05),

7. 7388093 - Gene for identifying individuals with familial dysautonomia (2008-06-17),

8. 7041448 - Gene encoding a new TRP channel is mutated in mucolipidosis IV (2006-05-09),

9. 6262250 - Kits for detecting polymorphisms associated with familial dysautonomia (2001-07-17),

10. 5998133 - Use of genetic markers to diagnose familial dysautonomia (1999-12-07),

Title: Susan A. Slaugenhaupt: Pioneering Innovator in mRNA Splicing

Introduction

Susan A. Slaugenhaupt, a notable inventor based in Hingham, Massachusetts, has made significant contributions to the field of molecular biology. With a remarkable ten patents to her name, she has dedicated her career to advancing our understanding of mRNA splicing and its implications in treating diseases of the central nervous system.

Latest Patents

Among her latest innovations are groundbreaking patents related to compounds for improving mRNA splicing. These compounds are designed to enhance splicing in cells, particularly in genes containing exons that end in the nucleotide sequence CAA. Additionally, her methods include preparations of these compounds and their applications in treating various central nervous system disorders. This innovative approach highlights her commitment to tackling complex biological challenges.

Career Highlights

Throughout her career, Susan has held positions at esteemed organizations such as the General Hospital Corporation and the United States of America as represented by the Secretary of the Department of Health and Human Services. Her work in these institutions has allowed her to further explore the intricacies of mRNA technology and its therapeutic potential.

Collaborations

In her pursuit of scientific advancement, Susan has collaborated with notable peers, including James F. Gusella and Anat Blumenfeld. These collaborative efforts have enriched her research and contributed significantly to the success of her inventions.

Conclusion

In conclusion, Susan A. Slaugenhaupt stands as a prominent figure in the development of mRNA splicing technologies. Her innovative patents reflect her dedication to advancing medical science and her impact on the treatment of central nervous system diseases. As she continues her groundbreaking work, her contributions promise to inspire future generations of inventors and researchers.

This text is generated by artificial intelligence and may not be accurate.